Methods for treating conditions associated with c-fms
AssigneeAmgen Inc.
InventorsKenneth Allan BRASEL, James F. SMOTHERS, Douglas Pat CERRETTI, Christopher MEHLIN, Jilin SUN, Stephen FOSTER
Life of this patent
Estimating the term…
Abstract
Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of c-fms to CSF-1, reduce monocyte migration into tumors, and reduce the accumulation of tumor-associated macrophages.
Claims21
A method for treating a condition associated with c-fms in a patient comprising administering an antibody or antibody fragment to the patient, wherein the condition is selected from a cancer, a bone disease, and an inflammatory disease, and wherein the antibody or antibody fragment binds human c-fms and comprises:
- (a) a heavy chain variable domain comprising a CDRH1, a CDRH2 and a CDRH3, wherein the CDRH1 comprises the amino acid sequence of SEQ ID NO:147, the CDRH2 comprises the amino acid sequence of SEQ ID NO:163, and the CDRH3 comprises the amino acid sequence of SEQ ID NO:186;
- and
- (b) a light chain variable domain comprising a CDRL1, a CDRL2 and a CDRL3, wherein the CDRL1 comprises the amino acid sequence of SEQ ID NO:193;
- the CDRL2 comprises the amino acid sequence of SEQ ID NO:214 and the CDRL3 comprises the amino acid sequence of SEQ ID NO:228.
A method for treating a condition associated with c-fms in a patient comprising administering an antibody or antibody fragment to the patient, wherein the condition is selected from a cancer, a bone disease, and an inflammatory disease, and wherein the antibody or antibody fragment binds human c-fms and comprises:
- (a) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:77;
- and
- (b) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:110.
A method for treating a condition associated with c-fms in a patient comprising administering an antibody or antibody fragment to the patient, wherein the condition is selected from a cancer, a bone disease, and an inflammatory disease, and wherein the antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO:11 and the light chain comprises the amino acid sequence of SEQ ID NO:44.
A method for treating a condition associated with c-fms in a patient comprising administering an antibody or antibody fragment to the patient, wherein the condition is selected from a cancer, a bone disease, and an inflammatory disease, wherein the antibody or antibody fragment is an antibody or antibody fragment that competes with a reference antibody for binding to the extracellular domain of human c-fms of SEQ ID NO:1, and wherein the reference antibody comprises:
- (a) a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:77;
- and
- (b) a light chain variable domain comprising the amino acid sequence of SEQ ID NO:110.
Dependencies are inferred from the claim text.